Table 1 Clinical characteristics of AAV patients at diagnosis
All of patients (n = 47) | RF-positive (n = 29) | RF-negative (n = 18) | P * | |
|---|---|---|---|---|
Age, years | 67 (61-76) | 66 (61-73) | 67 (58-80) | 0.79 |
Female, no (%) | 30 (64) | 18 (62) | 12 (67) | 1 |
Disease duration at diagnosis, days | 106 (42-231) | 87 (44-263) | 138 (37-232) | 0.56 |
EGPA, no (%) | 10 (21) | 8 (28) | 2 (11) | 0.28 |
GPA, no (%) | 14 (30) | 7 (24) | 7 (39) | 0.34 |
MPA, no (%) | 16 (34) | 9 (31) | 7 (39) | 0.75 |
UV, no (%) | 7 (15) | 5 (17) | 2 (11) | 0.69 |
Positivity of MPO-ANCA, no (%) | 39 (83) | 22 (76) | 17 (94) | 0.13 |
Positivity of PR3-ANCA, no (%) | 3 (6) | 1 (3) | 2 (11) | 0.69 |
BVAS | 14 (9-18) | 14 (12-22) | 12 (6-16) | 0.026 |
Presence of disease activity | ||||
General, no (%) | 24 (51) | 18 (62) | 6 (33) | 0.075 |
Arthralgia/Arthritis, no (%) | 7 (15) | 4 (14) | 3 (17) | 1 |
Cutaneous, no (%) | 10 (21) | 8 (28) | 2 (11) | 0.28 |
Mucous membranes/Eyes, no (%) | 2 (4) | 2 (7) | 0 (0) | 0.52 |
Ear/Nose/Throat, no (%) | 19 (40) | 11 (38) | 8 (44) | 0.76 |
Chest, no (%) | 25 (62) | 17 (59) | 8 (44) | 0.38 |
Pulmonary fibrosis, no (%) | 6 (13) | 4 (14) | 2 (11) | 1 |
Cardiovascular, no (%) | 2 (4) | 1 (3) | 1 (6) | 1 |
Abdominal, no (%) | 2 (4) | 2 (7) | 0 (0) | 0.52 |
Renal, no (%) | 17 (36) | 9 (31) | 8 (44) | 0.37 |
Nervous system, no (%) | 23 (49) | 20 (69) | 3 (17) | 0.001 |
Laboratory data | ||||
Serum albumin, g/dL | 3.5 (2.7-3.8) | 3.2 (2.6-3.8) | 3.8 (3.0-4.2) | 0.067 |
Serum creatinine, mg/dl | 0.7 (0.5-1.4) | 0.6 (0.5-1.0) | 0.7 (0.6-2.2) | 0.043 |
eGFR, ml/min/1.73 mm3 | 71 (33-94) | 81 (57-98) | 59 (18-81) | 0.028 |
Hemoglobin, g/dl | 11.8 (9.7-13.1) | 11.8 (10.0-13.1) | 12.1 (9.4-13.1) | 0.84 |
C3, mg/dl | 106 (86-127) | 120 (103-141) | 96 (86-125) | 0.40 |
C4, mg/dl | 30 (23-38) | 32 (21-43) | 27 (24-32) | 0.36 |